Avant Immunotherapeutics Receives National Institutes of Health (NIH) SBIR Phase 2 Award For Development And Manufacture Of Ty800 With VitriLife(R)

NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that it has been awarded a Phase 2 Small Business Innovation Research (SBIR) grant to support further development and manufacture of Ty800, the company’s single dose, oral typhoid vaccine. The National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) awarded this grant titled “Development and cGMP Manufacture of a Vitrified Typhoid Vaccine”, which provides approximately $750,000 in funding to AVANT.